Prevalence of HCV Infection in End Stage Renal Disease (ESRD) Patients on Maintenance Hemodialysis

HCV Infection in End Stage Renal Disease


  • Kishor Kumar Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
  • Bhagwan Das Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
  • Asma Naveed Bahria University of Medicine and Dental College, Karachi, Pakistan
  • Santosh Kumar Jinnah Sindh Medical University, Karachi, Pakistan
  • Muhammad Tassaduq Khan Dow University Hospital, Karachi, Pakistan
  • Rafia Memon Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan



Hepatitis C infection, End Stage Renal Disease, Maintenance Hemodialysis


Hepatitis C virus (HCV) is a significant cause of morbidity and mortality in haemodialysis patients. Patients on haemodialysis are at high risk for HCV, with frequency of infection several times higher than that in non-hemodialysis patients. Objective: To determine the frequency of HCV infection in End Stage Renal Disease (ESRD) patients on maintenance   hemodialysis. Methods: The Descriptive Cross-sectional study was conducted at Department of Nephrology, Liaquat University of Medical and Health Sciences Jamshoro. All patients above 18 years of age and below 60 years of age of both gender having end stage renal disease on maintenance hemodialysis with 3 months or more of maintenance hemodialysis were consecutively enrolled. Post hemodialysis patient’s serum was checked for anti HCV antibody by enzyme linked immune-sorbent assay (ELISA). Presence of anti HCV antibodies in serum detected by ELISA was labeled as HCV positive. Results: Of 90 patients, the mean age of the patients was 46.85 ±8.21 years. There were 54 (60%) males and 36 (40%) females. The mean duration of hemodialysis was 10.39 ±3.31 months. The frequency of HCV was found to be 21 (23.3%). A significant association of HCV was found with gender (p-value 0.006) whereas age (p-value 0.597) and duration of hemodialysis (p-value 0.715) was found to be insignificant. Conclusion: The frequency of HCV infection was found to be 23% in ESRD patients on maintenance hemodialysis. Early recognition and treatment of which improves the patient outcome.


Bahirwani R, Barin B, Olthoff K, Stock P, Murphy B, Rajender Reddy K, et al. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: Results from the national institutes of health multi‐site study. Liver Transplantation. 2013 Jun; 19(6): 619-26. doi: 10.1002/lt.23648

Shaikh GM, Khan DA, Khan FA, Ali MK. Validation of modified estimated glomerular filtration rate in chronic kidney disease patients. Journal of the College of Physicians and Surgeons Pakistan. 2013 Nov; 23(10): 793-97.

Zubair UB and Butt B. Assessment of quality of sleep and its relationship with psychiatric morbidity and socio-demographic factors in the patients of chronic renal disease undergoing hemodialysis. Journal of the College of Physicians and Surgeons Pakistan. 2017 Jul; 27(7): 427-31.

Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. Journal of the American Society of Nephrology. 2016 Aug; 27(8): 2238-46. doi: 10.1681/ASN.2016010030

Li M, Wang P, Yang C, Jiang W, Wei X, Mu X, et al. A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease?. Oncotarget. 2017 Feb; 8(6): 10692-702 doi: 10.18632/oncotarget.12896

Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar‐Zadeh K, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015 May; 61(5): 1495-502. doi: 10.1002/hep.27664

Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, et al. HCV response in patients with end stage renal disease treated with combination pegylated interferon α-2a and ribavirin. Journal of clinical gastroenterology. 2009 May; 43(5): 477-81. doi: 10.1097/MCG.0b013e318180803a

Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World journal of gastroenterology. 2017 Jan; 23(1): 151. doi: 10.3748/wjg.v23.i1.151

Ocal S, Selcuk H, Korkmaz M, Altun R, Yildirim AE, Akbas E. Effect of HLA on hepatitis C virus clearance and persistence in anti-HCV-positive end-stage renal disease patients. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association. 2014 May; 20(3): 175-81. doi: 10.4103/1319-3767.133007

Fabrizi F, Messa P, Martin P. Recent advances on hepatitis C virus in dialysis population. Kidney and Blood Pressure Research. 2014; 39(4): 260-71. doi: 10.1159/000355803

Poynard T, Yuen MF, Ratzin V, Lai CL. Viral hepatitis C. The Lancet. 2003 Dec; 362(9401): 2095-100. doi: 10.1016/S0140-6736(03)15109-4

Pujol FH, Ponce JG, Lema MG, Capriles F, Devesa M, Sirit F, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. Journal of Clinical Microbiology. 1996 Jul; 34(7): 1633-6. doi: 10.1128/jcm.34.7.1633-1636.1996

Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. American journal of kidney diseases. 2005 Apr; 45(4): 684-9. doi: 10.1053/j.ajkd.2004.12.014

Crook ED, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005 Sep; 28(9): 2187-91. doi: 10.2337/diacare.28.9.2187

Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002 Jul; 36(1): 3-10. doi: 10.1053/jhep.2002.34613

Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. 2001; 50(5): 1-43.

Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Journal of Infectious Diseases. 1993 Dec; 168(6): 1343-8. doi: 10.1093/infdis/168.6.1343

Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. Journal of the American Society of Nephrology. 2000 Oct; 11(10): 1896-902. doi: 10.1681/ASN.V11101896

Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. The American journal of gastroenterology. 1999 Dec; 94(12): 3576-82. doi: 10.1111/j.1572-0241.1999.01649.x

Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. The Journal of Infectious Diseases. 2000 Mar; 181(3): 852-8. doi: 10.1086/315355

Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999 Jan; 29(1): 257-63. doi: 10.1002/hep.510290123




How to Cite

Kumar, K. ., Das, B. ., Naveed, A. ., Kumar, S. ., Tassaduq Khan, M. ., & Memon, R. . (2023). Prevalence of HCV Infection in End Stage Renal Disease (ESRD) Patients on Maintenance Hemodialysis: HCV Infection in End Stage Renal Disease. Pakistan Journal of Health Sciences, 4(02), 95–98.



Original Article

Most read articles by the same author(s)